BioSpace News Archive

Beta Bionics, Inc. — The results of the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) were presented during a session hosted by Dr. Roy W. Beck and clinical investigators at the American Diabetes Association (ADA) 82nd Scientific Sessions.

Endoluxe is pleased to announce that they have entered into a multi-year exclusive distribution agreement specifically for the urology market with Dornier MedTech.

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has received Institutional Review Board (“IRB”) approval to begin the first-in-human Phase 1/2a clinical trial evaluating CYB003, its proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”).

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that Sam Samad will become Executive Vice President and Chief Financial Officer.

Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the third fiscal quarter ended April 30, 2022, and provided a business update on recent corporate and operational developments.

Psychemedics Corporation announced that it will be nominating Peter H. Kamin and Darius G. Nevin to serve as new members of its Board of Directors at its upcoming Annual Meeting of Stockholders to be held on August 12, 2022, and that Walter S. Tomenson, Jr. will be retiring from the Board as of the completion of his current term ending at the 2022 Annual Meeting.

Genmab A/S (Nasdaq:GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab.

bluebird bio, Inc. announced the outcome of the U.S. Food and Drug Administration’s Cellular, Tissue, and Gene Therapies Advisory Committee discussion of elivaldogene autotemcel for the treatment of early active cerebral adrenoleukodystrophy in patients less than 18 years of age who do not have an available and willing human leukocyte antigen -matched sibling hematopoietic stem cell donor.

Radiopharm Theranostics is pleased to announce that it has signed an exclusive sublicensing agreement with NeoIndicate, LLC to a PTPµ-targeted radiopharmaceutical agent, which was developed at CWRU in Ohio, USA.

Jaguar Health, Inc. (NASDAQ:JAGX) and Filament Health Corp. (NEO:FH) today announced that the companies have signed a letter of intent to enter a collaboration agreement to develop botanical prescription drugs for specific psychoactive target indications in the United States.